Relapse of hematologic malignancy is a major problem in allogeneic bone marrow transplantation (BMT). There is circumstantial evidence for the existence of a graft-versus-leukemia (GVL) effect exerted by cells from the donor marrow. It is postulated that Interleukin-2 (IL-2) may induce or amplify a GVL effect by activating appropriate donor T cells, by inducing secretion of other cytokines, and/or by activating non-specific effectors such as lymphokine-activated killer (LAK) cells. In humans, IL-2, alone or in combination with ex vivo-generated LAK cells, has induced remissions of some cancers, including lymphomas and acute leukemias. Moreover, IL-2/LAK therapy is not cross-resistant with chemoradiotherapy and should be most effective in a setting of minimal residual disease, such as exists early after BMT. The GVL effect has been documented only in recipients of unmodified allogeneic marrow-especially those with graft-versus-host disease (GVHD). Therefore, recipients of unmodified marrow, especially those without GVHD, who are at high risk for relapse, are appropriate subjects for attempts to amplify a GVL effect by stimulating T and/or non-T effector mechanisms. Recipients of T depleted marrow who are at low risk for GVHD but at high risk for relapse, are also appropriate subjects for attempts to induce a GVL effect since cells which acquire LAK activity on exposure to IL-2 in vitro are detectable in their blood very early after BMT. Accordingly, the specific aims of this project are as follows: (1) to assess the toxicity and immunomodulatory effects of IL-2 in a Phase Ib trial for patients who have received unmodified HLA-matched sibling marrow for hematologic malignancy, (2) based on data anticipated from 1, to design and perform a Phase II trial of a combination of IL-2 and ex vivo generated LAK cells to decrease the relapse rate in patients who have undergone HLA- matched sibling BMT and who are at high risk for leukemia relapse, (3) to assess the toxicity and immunomodulatory effects of IL-2 via a Phase Ib trial in patients who have undergone a T-depleted second HLA-matched allogeneic BMT for recurrent disease; and (4) based on data anticipated from 3, to design and perform a Phase II trial of a combination of IL-2 and ex vivo generated LAK cells to decrease the relapse rate in patients who have undergone T-depleted second HLA identical BMT for recurrent disease. The results should enhance our understanding of the GVL effect in BMT and might lead to an effective new treatment modality in the context of BMT for hematologic malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018029-19
Application #
3749236
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
19
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313

Showing the most recent 10 out of 1845 publications